Pinealon, Research Reference

Pinealon (chemical name Glu-Asp-Arg) is a synthetic tripeptide (3 amino acids) developed by the St. Petersburg Institute of Bioregulation and Gerontology, through the research of Professor Vladimir Khavinson and colleagues. The name reflects the compound’s proposed association with pineal gland function and its primary research focus on neuroprotective activity in neural tissue.

Pinealon belongs to the same family of bioregulatory peptides as Epitalon. Research has primarily been conducted at the Khavinson Institute and affiliated Russian institutions, with a focus on neuroprotection, cognitive function in animal models of ageing, retinal cell protection, and circadian rhythm regulation.

Quick Reference

Overview

Pinealon is derived from the same research programme that produced Epitalon and other Khavinson Institute bioregulatory peptides. The underlying research hypothesis proposes that short peptides can act as bioregulators of gene expression, influencing cellular function in specific tissues through interactions with chromatin and transcription factors.

Research has investigated Pinealon for its potential role in:

• Neuroprotection: Studies in animal models of ischaemic brain injury have reported reduced neuronal damage and improved outcomes following Pinealon administration. This represents the most frequently cited area of Pinealon research.
• Cognitive function: Studies in aged animal models have reported improvements in spatial memory and learning following Pinealon administration, with proposed mechanisms involving gene expression changes in neural tissue relevant to cognitive ageing.
• Circadian rhythm regulation: Research has proposed a role for Pinealon in pineal gland signalling and melatonin pathway regulation, consistent with the compound’s name and its proposed site of action.
• Retinal cell protection: Studies in models of retinal degeneration have reported that Pinealon reduced apoptosis in photoreceptor cells, suggesting a potential neuroprotective role in ocular tissue as well as central nervous system tissue.

Pinealon is not approved for human therapeutic use in any major Western jurisdiction and is classified as a research compound. The research base is concentrated at the Khavinson Institute and affiliated institutions; independent replication in Western literature is limited.

Mechanism

Pinealon is described within the bioregulatory peptide model proposed for Khavinson Institute compounds. Research has investigated potential interactions between Pinealon and chromatin structure, with proposed effects on gene expression in neural tissue. Reported areas of influence include genes involved in:

• Neuroprotection pathways: Studies have reported upregulation of genes associated with cell survival and resistance to ischaemic injury in neural tissue.
• Antioxidant response: Research has reported effects on antioxidant gene expression, consistent with findings reported for other Khavinson peptides.
• Transcription factor activity: Chromatin interaction studies have proposed that Pinealon may influence transcription factor binding at gene promoters relevant to neural cell function, consistent with the broader bioregulatory peptide model.

The precise molecular targets and signalling pathways have not been characterised to the standard of mainstream pharmacological research, and the proposed mechanisms remain at an early stage of investigation.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and published research literature. These are not medical recommendations.

Intranasal Protocol

Intranasal administration is the most commonly reported route for Pinealon in research accounts, reflecting the compound’s primary research focus on central nervous system effects. Commonly reported doses range from 5 mg to 10 mg per cycle, with intranasal preparations typically described at concentrations of 5 mg/mL.

• Cycle length: Commonly reported cycles of 10–20 consecutive days, consistent with the approach described for other Khavinson peptides
• Cycle frequency: Anecdotal research accounts describe 1–2 cycles per year, with rest periods of several months between cycles
• Frequency within cycle: Once daily administration is the most commonly reported approach during the active cycle
• Administration: Standard nasal spray delivery to both nostrils; the intranasal route is reported to allow potential nose-to-brain delivery via olfactory and trigeminal pathways

Subcutaneous Protocol

Subcutaneous injection is also reported as an alternative administration route. The dose range is similar to the intranasal protocol, with commonly reported doses of 5–10 mg per cycle administered over 10–20 days.

Reported Effects

The following effects have been reported in research literature and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes in general populations.

Neuroprotection

The most frequently cited area of Pinealon research concerns neuroprotection in models of ischaemic brain injury. Published studies have reported reduced neuronal damage, improved markers of cell survival, and better functional outcomes in animal models following Pinealon administration. Research has proposed that these effects are mediated through gene expression changes in neural tissue, though the precise mechanisms remain under investigation.

Cognitive Function

Studies in aged animal models have reported improvements in spatial memory and learning following Pinealon administration. These findings are cited as potential support for cognitive-focused research applications, particularly in the context of age-related cognitive decline. Anecdotal reports from research contexts include descriptions of improved mental clarity and focus, though controlled human trial data are not available.

Retinal Cell Protection

Research in models of retinal degeneration has reported that Pinealon reduced apoptosis in photoreceptor cells. This finding has generated interest in the potential application of Pinealon in research contexts related to age-related retinal changes, though the evidence base remains limited to animal and cell-based studies.

Circadian Rhythm and Melatonin Pathway

Research has proposed a role for Pinealon in pineal gland signalling and melatonin pathway regulation. Anecdotal reports sometimes describe effects on sleep quality, though the mechanism and magnitude of any such effect have not been characterised in controlled human research. This area of investigation is considered more preliminary than the neuroprotection findings.

Reported Subjective Effects

Anecdotal research accounts include descriptions of improved cognitive clarity, improved sleep quality, and general wellbeing during and following Pinealon research cycles. These subjective reports are not corroborated by controlled human trial data.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Pinealon is generally reported in anecdotal accounts as well tolerated. No significant adverse events have been described in the available research literature. The short peptide structure and the research dose ranges are considered relevant to the tolerability profile described in available accounts, though the compound has not undergone comprehensive human safety trials in controlled research chemical contexts.

Pinealon vs Epitalon

Both Pinealon and Epitalon are products of the same research programme at the Khavinson Institute, and they share a number of features:

The two compounds are sometimes used together in research contexts, reflecting their complementary areas of study. Epitalon is more widely referenced in the longevity research community; Pinealon is more specifically studied in the context of neuroprotection and cognitive ageing.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8°C): Preferred for extended storage; lyophilized Pinealon is reported stable for 12 months or more under refrigeration
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light sensitivity: Protect from light; store in an opaque or amber vial
• Room temperature: Acceptable for short-term transport, but refrigeration is preferred

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze a reconstituted solution
• Bacteriostatic water (BAC water) is the standard diluent for multi-use vials when using the subcutaneous route; sterile water for single-use preparations
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly along the inside wall of the vial. Swirl gently, do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is the difference between Pinealon and Epitalon? Both are synthetic peptides developed by Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology, but they differ in sequence and primary research focus. Epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide studied primarily for telomerase activation and longevity. Pinealon (Glu-Asp-Arg) is a tripeptide studied primarily for neuroprotection, cognitive function, and retinal cell protection. They share a research lineage and are sometimes used together in research contexts, but they are distinct compounds with distinct areas of study.

Why is intranasal administration commonly reported for Pinealon? Intranasal administration is commonly reported for Pinealon because it offers a potential nose-to-brain delivery pathway. The olfactory and trigeminal pathways provide a route by which small peptides may reach the central nervous system more directly, potentially circumventing some of the challenges posed by the blood-brain barrier. This is particularly relevant for a neuroprotective compound. Subcutaneous injection is also reported as an alternative route.

What is the research evidence base for Pinealon? The published research on Pinealon is concentrated at the Khavinson Institute and affiliated Russian institutions, consistent with the broader body of Khavinson peptide research. Studies have investigated neuroprotection in ischaemic injury models, cognitive function in aged animal models, retinal cell protection, and circadian rhythm regulation. Independent replication in Western research literature is limited. The findings are considered preliminary and have not been evaluated in large-scale controlled human trials.

What cycling protocols are commonly reported for Pinealon? Commonly reported protocols in research contexts describe cycles of 10 to 20 days, consistent with the approach reported for other Khavinson peptides including Epitalon. Commonly reported doses range from 5 to 10 mg per cycle. Cycle frequency is typically reported as 1 to 2 cycles per year, with rest periods of several months between cycles. Continuous daily use is not the standard approach in the available research literature.

Related Pages

Goals: Longevity & Healthy Aging · Cognitive Support & Focus

Class: Nootropic Peptides

Comparisons: Epitalon vs Pinealon

Also see: Epitalon (same research lineage, different mechanism focus)

References & Further Reading

• Khavinson VK, Yarygin VN, et al. Studies on Pinealon neuroprotection and retinal protection. St. Petersburg Institute of Bioregulation and Gerontology publications.
• Khavinson VK, et al. Peptide bioregulators and chromatin interactions in neural tissue. Bulletin of Experimental Biology and Medicine (various years).
• Khavinson VK, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 24(3–4), 233–240. PubMed →